| domain | established finding | evidence type/sample | key quantitative detail or variant | source/date/DOI |
|---|---|---|---|---|
| Identity / IDs | ADCA-DN is a rare Mendelian neurodegenerative syndrome caused by DNMT1; Open Targets maps the disease as MONDO_0011397 and the classic phenotype identifier is OMIM 604121 | Disease database mapping plus human discovery families | DNMT1 is the only associated target in Open Targets evidence returned here; OMIM phenotype number 604121 stated in primary literature | Open Targets association, accessed in tool output (pqac-00000000); Winkelmann et al., 2012, *Hum Mol Genet*, May 2012, https://doi.org/10.1093/hmg/dds035 (pqac-00000001) |
| Synonyms / nomenclature | Common names include “autosomal dominant cerebellar ataxia, deafness and narcolepsy” and “ADCA-DN”; later literature places it within broader “DNMT1-complex disorder” because of overlap with HSAN1E | Narrative disease-level synthesis from human cohorts | Distinction remains useful: ADCA-DN classically maps to exon 21 / C-terminal RFTS variants, HSAN1E more often exon 20 / N-terminal-middle RFTS variants | Baets et al., 2015, *Brain*, Apr 2015, https://doi.org/10.1093/brain/awv010 (pqac-00000004, pqac-00000006, pqac-00000008); Bi et al., 2020, *Neurol Genet*, Aug 2020, https://doi.org/10.1212/NXG.0000000000000456 (pqac-00000005, pqac-00000012) |
| Causal gene / variants | The landmark ADCA-DN variants are heterozygous missense DNMT1 exon 21 variants affecting the RFTS domain | Human exome/Sanger family studies | p.Ala570Val, p.Gly605Ala, p.Val606Phe; one report described a de novo exon 21 mutation in a Brazilian patient | Winkelmann et al., 2012, May 2012, https://doi.org/10.1093/hmg/dds035 (pqac-00000001, pqac-00000003); Pedroso et al., 2013, *Sleep*, Aug 2013, https://doi.org/10.5665/sleep.2898 |
| Inheritance / onset | Autosomal dominant inheritance with age-dependent, usually adult onset | Human pedigrees | Typical onset in 30s–40s; narcolepsy-cataplexy and deafness often precede ataxia and dementia | Winkelmann et al., 2012, May 2012, https://doi.org/10.1093/hmg/dds035 (pqac-00000001, pqac-00000003); Moghadam et al., 2014, *Sleep Med*, May 2014, https://doi.org/10.1016/j.sleep.2013.09.028 (pqac-00000017) |
| Clinical course | Disease is progressive and multisystem neurologic involvement expands over time | Human family cohorts and expanded case series | Early symptoms: narcolepsy/deafness; later cerebellar ataxia, cognitive decline/dementia, optic atrophy, neuropathy, psychiatric manifestations, diabetes mellitus | Winkelmann et al., 2012, May 2012, https://doi.org/10.1093/hmg/dds035 (pqac-00000001); Davis et al., 2023, *Hum Mol Genet*, Aug 2023, https://doi.org/10.1093/hmg/ddad123 (pqac-00000002, pqac-00000010) |
| Core phenotypes | Canonical phenotype triad is narcolepsy/cataplexy, sensorineural deafness, and cerebellar ataxia; dementia is frequent later | Human clinical cohorts | CSF hypocretin-1 reported low/undetectable in the discovery paper; additional features can include optic atrophy, hallucinations, seizures, lymphedema, neuropathy | Winkelmann et al., 2012, May 2012, https://doi.org/10.1093/hmg/dds035 (pqac-00000001, pqac-00000007); Baets et al., 2015, Apr 2015, https://doi.org/10.1093/brain/awv010 (pqac-00000004, pqac-00000008) |
| Presymptomatic / early markers | Sleep and metabolic abnormalities may predate overt neurologic symptoms in mutation carriers | Human presymptomatic family study | In 2 asymptomatic daughters, SOREMPs were detected and proton MRS showed increased cerebellar myoinositol despite normal neurologic exam, audiometry, ophthalmology, and structural MRI | Moghadam et al., 2014, May 2014, https://doi.org/10.1016/j.sleep.2013.09.028 (pqac-00000017) |
| Imaging / neurophysiology | Neuroimaging can show brain or spinal changes; neurophysiology often supports sensory axonal neuropathy | Human case series | Global brain atrophy in 12/14 MRI cases in broader DNMT1 disorder cohort; case reports include T2 hyperintense enhancing lesions, PET hypometabolism, posterior column atrophy, abnormal evoked potentials | Baets et al., 2015, Apr 2015, https://doi.org/10.1093/brain/awv010 (pqac-00000006, pqac-00000011); Bi et al., 2020, Aug 2020, https://doi.org/10.1212/NXG.0000000000000456 (pqac-00000012) |
| Prognosis / natural history | Available natural-history evidence suggests substantial morbidity and reduced survival, but data are sparse and mostly from aggregated DNMT1-complex cohorts rather than pure ADCA-DN cohorts | Human retrospective cohort | Mean onset 37.7 years and average survival 53.6 years in Baets et al.; cognitive decline in 89% by age 45 in that broader cohort | Baets et al., 2015, Apr 2015, https://doi.org/10.1093/brain/awv010 (pqac-00000006, pqac-00000011) |
| Molecular mechanism | ADCA-DN variants localize to the DNMT1 RFTS domain, disrupting maintenance methylation and protein behavior; disease mechanism is not simple haploinsufficiency | Human genetics, cell biology, mechanistic review | A570V/G605A/V606F weaken RFTS-catalytic domain interaction; mutant DNMT1 can mislocalize, lose heterochromatin binding, aggregate, and drive aggresome/autophagy-related proteostasis defects | Baets et al., 2015, Apr 2015, https://doi.org/10.1093/brain/awv010 (pqac-00000006, pqac-00000011); Davletgildeeva & Kuznetsov, 2024, *Biomolecules*, Sep 2024, https://doi.org/10.3390/biom14091117 (pqac-00000009) |
| 2023 iPSC / iNeuron omics | Patient-derived fibroblasts, iPSCs, and induced neurons show cell-type-specific methylome/transcriptome disruption in ADCA-DN | Human in vitro disease models | Variants studied: Ala570Val, Gly605Ala, Val606Phe; methylation and expression were negatively correlated in iPSCs/iNs; ZFP57 promoter hypomethylation/upregulation; phenotype-linked genes included PDGFB, PRDM8, NR2F1 | Davis et al., 2023, Aug 2023, https://doi.org/10.1093/hmg/ddad123 (pqac-00000002, pqac-00000010) |
| Additional mechanistic models | RFTS mutations can trigger instability and internal cleavage of DNMT1, implying mixed loss- and gain-of-function effects | Mouse and cell models, primarily HSAN1E-oriented but mechanistically relevant to DNMT1 RFTS disease | Specific truncated ~75–80 kDa DNMT1 species near aa ~501 proposed; heterozygous knock-in mice had reduced DNMT1 and impaired learning/memory; homozygous mutants died around E10.5 | Wang et al., 2021, *Sci Adv*, Sep 2021, https://doi.org/10.1126/sciadv.abe8511 (pqac-00000014, pqac-00000015) |
| Diagnostics | Diagnosis is primarily molecular, supported by characteristic sleep/hearing/ataxia/cognitive phenotype and family history; WES/WGS can be especially useful when phenotype is atypical or overlaps neuromuscular disease | Human genetics case reports and clinic practice article | Sanger sequencing of DNMT1 exon 21 was used in targeted familial testing; later literature emphasizes WES/WGS to improve diagnostic yield in adults | Moghadam et al., 2014, May 2014, https://doi.org/10.1016/j.sleep.2013.09.028 (pqac-00000017); Dratch et al., 2024, *Biology*, Feb 2024, https://doi.org/10.3390/biology13020093 (pqac-00000016) |
| Real-world intervention | Cochlear implantation can improve hearing in DNMT1-complex disorder and is the clearest disease-specific real-world intervention reported in the retrieved evidence | Human case report within clinical series | One patient with p.T497P had “significant hearing improvements at all tested frequencies (250–6,000 Hz)” after left cochlear implant | Bi et al., 2020, Aug 2020, https://doi.org/10.1212/NXG.0000000000000456 (pqac-00000012) |
| Supportive care / implementation | Management remains symptomatic and multidisciplinary: sleep medicine, audiology, neurogenetics, rehabilitation, neuropsychology, and genetic counseling | Case-series based care observations | Example supportive measures reported include IV immunoglobulin for hypogammaglobulinemia in one DNMT1-complex case and use of advanced imaging/neurophysiology for surveillance | Bi et al., 2020, Aug 2020, https://doi.org/10.1212/NXG.0000000000000456 (pqac-00000012); Dratch et al., 2024, Feb 2024, https://doi.org/10.3390/biology13020093 (pqac-00000016) |
| Epidemiology gap | Extremely rare disease with very few pedigrees described; robust prevalence/incidence estimates are not available in the retrieved evidence | Literature review and early family reports | Moghadam 2014 states only the original Swedish family plus five further pedigrees recognized worldwide at that time | Moghadam et al., 2014, May 2014, https://doi.org/10.1016/j.sleep.2013.09.028 (pqac-00000017); Patil et al., 2024, Jul 2024, https://doi.org/10.1186/s13148-024-01697-9 (pqac-00000013) |
| Trials gap | No disease-specific interventional clinical trials for ADCA-DN were identified in the retrieved tool results | Clinical trials search result | Tool search found no relevant ADCA-DN/DNMT1 ataxia-deafness-narcolepsy intervention trial | ClinicalTrials.gov tool search in conversation returned no relevant trials (pqac-00000000) |
| Model limitations | Current models are informative but incomplete for ADCA-DN | Mouse/cell model interpretation | 2021 knock-in mice modeled HSAN1E-equivalent RFTS mutations and noted that full neuronal phenotypes, “including hearing, remain to be determined”; cognitive defects were modest relative to human disease | Wang et al., 2021, Sep 2021, https://doi.org/10.1126/sciadv.abe8511 (pqac-00000014, pqac-00000015) |


*Table: This compact table summarizes the most actionable and best-supported findings for autosomal dominant cerebellar ataxia, deafness and narcolepsy across identity, phenotype, mechanism, diagnostics, and care. It emphasizes where evidence is strong, where newer 2023-2024 data add insight, and where important gaps remain.*